MNPR-101-Lu shows high specificity, durable uptake in pancreatic cancer model
March 6, 2024
Monopar Therapeutics Inc. has released promising preclinical imaging data of a therapeutic radioisotope bound to its proprietary urokinase plasminogen activator receptor (uPAR)-targeting agent, MNPR-101.